Primary role was to implement technologies to support CDMO biological manufacturing platforms. Taking a strategic approach to either develop technologies internally or in-license validated platforms to offer solutions for near-term and future deliverables. • Developed and implemented the technical strategy to bring CDMO services to market• Championed company innovation and ingrained process quality from Executive Leadership Team (ELT) to bench scientist• Conceived and directed the implementation of proprietary, IP-free mammalian expression platforms for various recombinant protein entities• Established a remote multi-functional lab and performed as Site Head. Lab focus included platform development, case study data generation, and early CDMO cell line and protein production services. Lab capabilities included molecular biology, cell line development, protein purification and basic analytical services• Managed cross-site development of market-relevant case-study data generation to promote commercialization• Mentored in-house scientists and clients on desirable attributes for protein biologics, including therapeutic lead-candidate design• Remotely managed cell line development team at company headquarters in Oklahoma City• Identified, assessed and in-licensed relevant technology needed to support business needs

Primary role was to build and develop a highly efficient Protein Sciences group capable of supporting company objectives from therapeutic molecule discovery through to preclinical validation.• Built and led a highly efficient team capable of molecular biology, protein production (engineering/ mammalian expression/ purification/ characterization), cell line engineering and therapeutic concept identification • Developed and industrialized the proprietary StitchMabs high-throughput multi-specific antibody screening platform, which resulted in successful IND filing of a current Phase I entity• Supervised the screening of thousands of therapeutic entities (including monoclonals, multi-specifics, antibody-related fragments, fusion proteins etc.), and collaborated cross-function to identify pre-clinical and clinical candidates. Successful candidates are currently in Phase I and II of clinical trials• Promoted cross-functional collaborations to drive success and employee development• Collaborated with external partners and CROs to ensure project success• Conceived and optimized protein deliverables for internal and external needs• Improved data capture and functionality by working closely with information technology support• Effectively managed departmental budget

GlycoFi (A wholly owned subsidiary of Merck & Co., Inc.)Primary tasks were enhancing the proprietary glycoengineered Pichia pastoris expression platform to offer expanded therapeutic applications, and to develop therapeutic proteins.Experience has included key roles in leading technical aspects of platform and therapeutic protein development, participating in cross-functional groups, collaborating with external partners, and supporting the Merck legal group.Responsibilities and achievements:• Led the Pathway Engineering Group to identify and develop an expanded repertoire of glycoforms for therapeutic protein application in the glycoengineered Pichia pastoris expression platform • Supervised key aspects of novel, biosimilar and biobetter therapeutic pre-clinical development programs. Several therapeutic molecules demonstrated clinical opportunities but were de-prioritized for business and commercial reasons• Optimized recombinant expression of therapeutic proteins and enzymes for technical applications • Established a Saccharomyces cerevisiae-based strategy for enzyme evolution• Technical experience in: molecular biology (cloning, PCR, mutagenesis, library generation, host cell engineering), protein analysis (SDS-PAGE, western blotting, proteolytic digestion, in vitro activity assays), glycobiology (in vitro and in vivo glycan manipulation, interpretation of glycan analytics), protein purification (affinity tagged), recombinant protein expression (bacterial, fungal and mammalian expression platforms) • Identified inefficiencies in sample processing and led a team in providing a Six Sigma solution, saving scientists hours of computer manipulations per week.• Collaborated with external experts-in-the-field to develop new therapeutic protein opportunities• Worked closely with the Merck legal group to file, execute and defend numerous patent disclosures• Hired and managed fellow researchers (including research assistants and PhD scientists)

Primary role was glycoengineering the yeast strain Pichia pastoris to be a therapeutic protein expression platform.Responsibilities and achievements:• Accredited with achieving three of the six GlycoFi technical milestones• Collaborated with fellow scientists in a high energy biotech environment to ensure success of company goals• Set up a mammalian cell expression laboratory• Conceived and implemented strategies to circumvent competing intellectual property• Managed fellow researchers (including undergraduates, research assistants and PhD scientists)

Primary role was characterizing a key metabolic cell signaling protein through recombinant expression and mutagenic analyzes.Responsibilities and achievements:• Established bacterial expression of a difficult to express subunit of a mammalian cell signaling protein• Generated and characterized site-directed mutants of the same cell signaling protein• Undertook a six week sabbatical in a collaborating laboratory in Melbourne (Australia) to transfer technical expertise to PhD scientists and research assistants• Supervised undergraduates and research assistants